Abstract:Abstract Glioblastoma multiforme (GBM) is a highly malignant, non-curative tumor of the primary central nervous system with dismal prognosis. Treatment options are limited and conventional therapies, including surgery, radiotherapy, chemotherapy have not resulted in major improvements in the survival of patients. The advent of chimeric antigen receptor (CAR) T cell technology has opened new perspectives in the fight against cancer. Therefore, cell surface proteins that are suitable as targets for CAR T cells need to be identified. When considering a certain protein as a target for immunotherapy, two aspects have to be taken into account: Coverage of tumor cells as a factor for efficacy and the expression in healthy tissues under physiological conditions. The latter represents a potential threat, due to on-target/off-tumor toxicity. The novel MACSima™ Imaging Platform enables high-content, cyclic fluorescence-based imaging of individual biological samples in a fully automated fashion. We applied this method to subclassify different glioblastoma samples, to identify new glioblastoma marker and to analyze the toxicity profile of these markers. A selection of 96 markers, identified through flow cytometric analysis of cell surface expression on primary glioblastoma-derived xenografts, was used for characterization of diverse primary glioblastoma samples using the MACSima™ Imaging Platform. Cryosections were fixed using acetone, and each specimen was exposed to the 96 fluorochrome-conjugated antibodies by cycles of i) staining with antibody, ii) image acquisition, and iii) erasure of the fluorescence signal. Previously published markers, such as PDGFRα, p53, synaptophysin, CD44, nestin, podoplanin, GFAP, and EGFR were used to subclassify the glioblastoma into oligodendrocyte precursor (OPC), differentiated oligodendrocyte (DOC), astrocytic and mesenchymal (AsMes) or mixed subtype, according to Motomura et al.1 Analysis of well-established glioblastoma markers already used in CAR T cell-based clinical trials, such as IL-13Rα22, EGFRvIII3, or ErbB24 revealed a broad inter- and intratumor diversity of expression. Segmentation and correlation analysis enabled the selective detection of tumor cells and the identification of new glioblastoma specific markers, which might be candidates for future CAR T cell based therapies. To analyze the risk of “on-target/off-tumor” toxicity, differential expression of these markers on tumor tissue versus healthy tissue was determined. A higher expression level was detected on tumor tissue in comparison to healthy tissue in case of some candidates, underlining the capability of these markers for future CAR T cell-based therapies. Citation Format: Sandy Reiß, Stefan Tomiuk, Jutta Kollet, Jan Drewes, Melanie Jungblut, Andreas Bosio. Comprehensive cyclic immunofluorescent analysis reveals new target candidates for CAR T cell based immunotherapy of glioblastoma multiforme [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6646.

Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy

Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens

Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

Abstract 6646: Comprehensive cyclic immunofluorescent analysis reveals new target candidates for CAR T cell based immunotherapy of glioblastoma multiforme

Landscape of surfaceome and endocytome in human glioma is divergent and depends on cellular spatial organization

BIOM-20. PROTEOMICS PROVIDES POTENTIAL THERAPEUTIC APPROACHES TO GLIOBLASTOMA TREATMENT: RESULTS FROM THE CLINICAL PROTEOMICS TUMOR ANALYSIS CONSORTIUM (CPTAC)

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach

Abstract LB432: Identification of novel drug targets using the ADAPT biotargeting system on FFPE tissue from patients with glioblastoma multiforme

Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance

SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS

Exploring Extracellular Vesicle Surface Protein Markers Produced by Glioblastoma Tumors: A Characterization Study Using In Vitro 3D Patient-Derived Cultures

Genome-Scale Metabolic Modeling of Glioblastoma Reveals Promising Targets for Drug Development

System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Emerging Lipid Targets in Glioblastoma

T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression

Current approaches in glioblastoma multiforme immunotherapy

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment